Introduction: We examined the tolerability of dosage methods of naftopidil in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH/male LUTS).
Patients And Methods: A total of 80 patients with BPH/male LUTS who had an International Prostate Symptom Score (IPSS) >or=8 and IPSS quality of life (QoL) >or=2 were enrolled and randomly administered naftopidil for 8 weeks at either 75 mg once daily (OD) in the evening (group O; n = 41) or 25 mg thrice daily (TID) in the morning, afternoon and evening (group T; n = 39).
Results: IPSS total score, IPSS-QoL and BPH impact index (BII) were significantly improved for both groups at 8 weeks after starting treatment compared to baseline. IPSS total score and daytime and 24-hour voiding frequencies were significantly improved at 8 weeks after starting treatment for group O in comparison to group T. Group O showed a significantly better degree of change in BII in comparison to group T.
Conclusions: Naftopidil 75 mg OD in the evening was better tolerated than naftopidil 25 mg TID for the objective parameter and BII.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000315994 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between alpha blocker use and the risk of fractures in patients with chronic kidney disease: a cohort study.
BMC Nephrol
December 2024
Department of Nephrology, Graduate School of Medicine, Nagoya University, Tsurumai-Cho 65, Showa-Ku, Nagoya City, Aichi Prefecture, Japan.
Article Synopsis
- Alpha blockers (ABs) are commonly given to patients with chronic kidney disease (CKD) who often deal with high blood pressure, but the link between ABs and fracture risk is unclear, prompting this study.
- The research analyzed a large cohort from a Japanese medical database, focusing on patients newly prescribed either ABs for hypertension or non-AB antihypertensive medications, with separate analyses for males and females.
- The findings showed that while males had no increased fracture risk with AB use, females using ABs for voiding dysfunction exhibited a significant rise in fracture risk compared to those on antihypertensive ABs.
Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis.
Sci Rep
May 2024
Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Mohali, Punjab, India.
Despite the availability of various drugs for benign prostatic hyperplasia (BPH), alpha(α)-blockers are the preferred first-line treatment. However, there remains a scarcity of direct comparisons among various α-blockers. Therefore, this network meta-analysis (NMA) of randomized controlled trials (RCTs) aimed to evaluate the efficacy and safety of α-blockers in the management of BPH.
View Article and Find Full Text PDFAssociation of silodosin, tamsulosin, and naftopidil with delirium: analysis of the pharmacovigilance database in Japan.
Int J Clin Pharm
October 2023
Department of Pharmacy, Okayama Saiseikai General Hospital, 2-25 Kokutaicho, Kita-ku, Okayama-shi, Okayama, 700-8511, Japan.
Background: An association between adrenergic alpha-1 receptor antagonists and delirium has been suggested, but the details are unclear.
Aim: This study investigated the association between adrenergic alpha-1 receptor antagonists and delirium in patients with benign prostatic hyperplasia using the Japanese Adverse Drug Event Report database.
Method: First, disproportionality analysis compared the frequency of delirium in the adrenergic alpha-1 receptor antagonists silodosin, tamsulosin, and naftopidil.
Effect of α1D-adrenoceptor blocker for the reduction of ureteral contractions.
Investig Clin Urol
January 2023
Department of Urology, Hanyang University College of Medicine, Seoul, Korea.
Article Synopsis
- Urolithiasis is increasingly common, and the study investigates how α1D-adrenoceptor blockade affects ureteral contraction, as α1D-AR is prevalent in ureteral smooth muscle.
- The research involved testing the effects of drugs like silodosin, tamsulosin, and naftopidil on contraction in smooth muscle tissues from rats and humans, using an organ bath system.
- Results indicated that naftopidil significantly reduced contractility in both rat and human ureteral tissues, suggesting it could be an effective treatment for patients experiencing ureteral stones.
Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis.
Arch Ital Urol Androl
June 2022
U-merge Ltd. (Urology for emerging countries), London-Athens-Dubai; and Sobeh's Vascular and Medical Center, Dubai Health Care City, Dubai.
Article Synopsis
- Alpha-adrenoreceptor antagonists, or alpha-blockers, are commonly used to treat conditions like high blood pressure and benign prostatic hyperplasia, but can impact sexual function differently based on the specific drug used.
- A systematic review and meta-analysis of 75 randomized controlled trials found that alpha-blockers significantly increased the odds of ejaculatory disorders, especially with uroselective agents like silodosin.
- However, there were no significant differences in the odds of erectile dysfunction when comparing alpha-blockers to placebo, indicating that not all sexual side effects are equally likely with these medications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!